PK-DB: pharmacokinetics database for individualized and stratified computational modeling
暂无分享,去创建一个
Jan Grzegorzewski | Janosch Brandhorst | Dimitra Eleftheriadou | Kathleen Green | Matthias König | M. König | J. Grzegorzewski | Janosch Brandhorst | K. Green | D. Eleftheriadou
[1] Tudor Groza,et al. The Monarch Initiative: an integrative data and analytic platform connecting phenotypes to genotypes across species , 2016, bioRxiv.
[2] Erik Schultes,et al. The FAIR Guiding Principles for scientific data management and stewardship , 2016, Scientific Data.
[3] Gang Fu,et al. Disease Ontology 2015 update: an expanded and updated database of human diseases for linking biomedical knowledge through disease data , 2014, Nucleic Acids Res..
[4] A. Rostami-Hodjegan,et al. Precision dosing in clinical medicine: present and future , 2018, Expert review of clinical pharmacology.
[5] A. Staib,et al. 4-quinolones inhibit biotransformation of caffeine , 2004, European Journal of Clinical Pharmacology.
[6] J. Ioannidis. Reproducible pharmacokinetics , 2019, Journal of Pharmacokinetics and Pharmacodynamics.
[7] K. Seng,et al. Population pharmacokinetics of caffeine in healthy male adults using mixed‐effects models , 2009, Journal of clinical pharmacy and therapeutics.
[8] D R Mould,et al. Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development: Part 3—Introduction to Pharmacodynamic Modeling Methods , 2014, CPT: pharmacometrics & systems pharmacology.
[9] Sherri de Coronado,et al. NCI Thesaurus: A semantic model integrating cancer-related clinical and molecular information , 2007, J. Biomed. Informatics.
[10] Tudor Groza,et al. Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources , 2018, Nucleic Acids Res..
[11] U. Fuhr,et al. Ciprofloxacin-caffeine: a drug interaction established using in vivo and in vitro investigations. , 1989, The American journal of medicine.
[12] The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects , 2013, European Journal of Clinical Pharmacology.
[13] L Aarons,et al. Population pharmacokinetics: theory and practice. , 1991, British journal of clinical pharmacology.
[14] U. Hofmann,et al. Evidence for morphine‐independent central nervous opioid effects after administration of codeine: Contribution of other codeine metabolites , 2006, Clinical pharmacology and therapeutics.
[15] L. Benet,et al. Pharmacokinetic parameters: which are necessary to define a drug substance? , 1984, European journal of respiratory diseases. Supplement.
[16] D. Mays,et al. Inhibition of elimination of caffeine by disulfiram in normal subjects and recovering alcoholics , 1986, Clinical pharmacology and therapeutics.
[17] Johan Gabrielsson,et al. Non-compartmental analysis. , 2012, Methods in molecular biology.
[18] D. Moher,et al. Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement , 2015, Clinical Pharmacokinetics.
[19] D R Mould,et al. Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development , 2012, CPT: pharmacometrics & systems pharmacology.
[20] A. Staib,et al. Decrease of caffeine elimination in man during co-administration of 4-quinolones. , 1987, The Journal of antimicrobial chemotherapy.
[21] Leonid Hanin,et al. Why statistical inference from clinical trials is likely to generate false and irreproducible results , 2017, BMC Medical Research Methodology.
[22] Christoph Steinbeck,et al. ChEBI in 2016: Improved services and an expanding collection of metabolites , 2015, Nucleic Acids Res..
[23] D R Mould,et al. Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods , 2013, CPT: pharmacometrics & systems pharmacology.
[24] C. Tornøe,et al. Reporting guidelines for population pharmacokinetic analyses , 2015, Journal of Pharmacokinetics and Pharmacodynamics.